Galidesivir triphosphate is a substrate for viral RNA-dependent RNA polymerase (RDRP), resulting in termination of viral RNA replication and thus serves as an antiviral. Galidesivir triphosphate inhibits HCVNS5B RNA polymerase activity and protects mice against Ebola. Galidesivir triphosphate (Immucillin-A triphosphate) is converted by the prodrug Galidesivir.
MK-3281 is a potent, orally bioavailable hepatitis C virus NS5Bpolymerase finger-loop inhibitor. It is also an inhibitor of attractive molecular properties with good potency in HCV subgenomic replication trials and suitable for clinical candidates.